Methods and use of compounds that bind to HER2/neu receptor complex
This application describes pharmaceutical compositions, commercial packages, and methods for inhibiting cell proliferative disorders, especially those disorders, including Her2 related cancers, characterized by overactivity and/or inappropriate activity of a receptor tyrosine kinase, and methods for imaging an HER-2 expressing tumor.
1. A method of inhibiting a cell proliferative disorder characterized by over-activity and/or inappropriate activity of Her2, the method comprising administering to a patient in need of such treatment a pharmaceutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt or prodrug thereof:
wherein X is independently at each occurrence alkyl, halo, perfluoromethyl, hydroxy, carboxylic acid, ester, amide, substituted alkoxy, substituted thiol, substituted acyl, nitrile, or substituted amino group.
2. The method of claim 1 wherein X is halo.
3. The method of claim 1 wherein the compound of Formula (I) is
4. The method of claim 1 wherein the cell proliferative disorder is cancer.
5. The method of claim 1 wherein the cell proliferative disorder affects a breast, prostate, lung, pancreas, ovary, or stomach.
6. The method of claim 1 wherein the patient is a human.
7. The method of claim 1 further comprising administering a pharmaceutically effective amount of an anti-cancer agent or performing a non-drug therapy or both to the patient.
8. The method of claim 7 wherein the compound of Formula (I) and the anti-cancer agent are administered at the same time.
9. The method of claim 7 wherein the non-drug therapy is surgery, hypertensive chemotherapy, genetherapy, thermotherapy, cryotherapy, photodynamic therapy, laser cauterization and/or radiotherapy.
10. A pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt or prodrug thereof, in an amount effective to inhibit a cell proliferative disorder characterized by over-activity and/or inappropriate activity of Her2, and a pharmaceutically acceptable excipient:
wherein X is independently at each occurrence an alkyl, halo, perfluoromethyl, hydroxy, carboxylic acid, ester, amide, substituted alkoxy, substituted thiol, substituted acyl, nitrile, or substituted amino group.
11. The composition of claim 10 wherein X is halo.
12. The composition of claim 10 wherein the compound of Formula (1) is
13. The composition of claim 10 wherein the cell proliferative disorder is cancer.
14. The composition of claim 10 wherein the cell proliferative disorder affects a breast, prostate, lung, pancreas, ovary, or stomach.
15. The composition of claim 10 wherein the cell proliferative disorder is psoriasis, atherosclerosis or restenosis.
16. The composition of claim 10 wherein the patient is a human.
17. A commercial package comprising the pharmaceutical composition of claim 10 , at least one anti-cancer agent, and a written matter associated therewith, the written matter stating that the pharmaceutical composition can or should be used for treatment of a disease caused by overexpression or activation of Her2.